reports
Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Inn...
Pluri CEO Issues Shareholder Letter Highlighting Strategic Growth, Innovation, and Global Market Expansion Major milestones include entry into cultivated cacao and coffee markets and progress toward commercial-scale productionCompany reports nearly 400% revenue growth in the first nine months of fiscal year 2025 compared to the same period in fiscal year 2024, driven by its CDMO and AgTech businesses, and is advancing new food tech partnerships and licensing opportunities HAIFA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) (“Pluri” or the “Company”), a leadi...
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFo...
Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd. Acquisition of approximately 71% stake in Kokomodo Ltd.Acquisition uniquely combines Pluri's mass-scale cell production expertise with Kokomodo Ltd.’s ability to craft real, controlled, climate-resilient cacao using cellular agriculture technology HAIFA, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures...
Pluri Announces Expansion of Intellectual Property Portfolio with Two ...
Pluri Announces Expansion of Intellectual Property Portfolio with Two Granted Patents for 3D Expansion of Immune Cells in the United States and Israel Latest granted patents reinforce Pluri’s position as a leader in Mucosal-Associated Invariant T (“MAIT”) cell-based cell therapies for solid cancersPluri’s MAIT platform enables commercial scale production of powerful immune cells as a potential first-in-class, ready to use, “off-the-shelf” therapy for cancer patientsPluri’s MAIT platform addresses the global immune cell engineering market, projected to reach approximately by 2030, and the g...
- Ari Zoldan
Pluri Inc. - Initiation of Coverage
Pluri Inc. is a biotechnology company leveraging proprietary 3D cell expansion technology to provide scalable cell-based solutions across regenerative medicine, food technology, contract development and manufacturing (CDMO), and agricultural sectors. The company's innovative PluriMatrix platform, utilizing an automated cGMP-approved bioreactor system, ensures high-quality, consistent, and cost-effective industrial-scale cell production applicable to pharmaceuticals, biologics, cultivated foods, ...
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enh...
Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness Strategic initiative to address Ukraine’s urgent need for radiation countermeasures Hemafund's infrastructure ensures secure storage and rapid deployment of emergency treatments Collaboration may potentially generate over $100 million in value for both parties HAIFA, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to cr...
Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Produ...
Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution Food Industry Leader Teams With Ever After Foods to Accelerate Cultivated Meat Market Development KEMPTTHAL, Switzerland and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Foodtech innovator (EAF) and global food leader today announced an expansive cultivated meat collaboration to help food producers around the globe produce cultivated meat efficiently at mass scale. Bühler and Ever After Foods will work together to bring a commercial-scale cultivated meat production system, which allows com...
Pluri Secures Additional $3.5 Million Investment from Major Shareholde...
Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million New investment follows recent private placement of $6.5 million with global investor and entrepreneur, Mr. Alejandro WeinsteinFunds are intended to support Pluri’s growth and execution strategy as a global leader in cell-based technology HAIFA, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PLUR) (TASE:PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a coll...
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, ...
Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition Private placement of $6.5 million with a global investor and entrepreneur, Mr. Alejandro Weinstein, who will join Pluri’s Board of DirectorsPluri to purchase approximately 71% of Kokomodo Ltd.’s shares, a leading AgTech company focused on the production of cacao, subject to shareholder approval HAIFA, Israel, Jan. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PLUR) (TASE:PLUR) ("Pluri" or the “Company"), a leading biotechnology company leveraging its proprietary platform for cell-based ...
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Str...
Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease HAIFA, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), an innovator in the development of leading cell-based technologies for various indications, congratulates Mesoblast Ltd. (“Mesoblast”) and its Chief Executive Officer, Silviu Itescu, on the U.S. Food and Drug Administration (the “FDA”) approval of the first MSC-based therapy for steroid-refractory acute graft-versus-host disease (“SR-aGVHD”). T...
Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awa...
Pluri Shortlisted for CDMO of the Year Award by Advanced Therapies Awards 2025 PluriCDMO™, the Company’s contract development and manufacturing organization, recognized as a leading manufacturing collaborator offering scalability and mass scale production to a growing number of innovative life science companies HAIFA, Israel, Dec. 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: PLUR) (TASE:PLUR) ("Pluri" or the “Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that its ™ busines...
Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Rad...
Pluri Evaluates Readiness for Mass Production of PLX-R18 for Acute Radiation Syndrome Amid Rising Nuclear Threat Concerns HAIFA, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced that it is assessing its readiness to initiate mass production of PLX-R18, a novel potential treatment for hematopoietic complications of the acute radiation syndrome (H-ARS) following exposure to nuclear radi...
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunoth...
Pluri Collaborates with Bar-Ilan University to Advance Cancer Immunotherapy for Solid Tumors, Supported by Israel Innovation Authority The Israel Innovation Authority will fund Pluri and BIRAD's collaboration to advance MAIT Cell Therapy, led by Professor , Head of the laboratory of tumor immunology and immunotherapy at Bar-Ilan UniversityMAIT cells hold immense potential for immunotherapy and the treatment of solid tumors compared to conventional T-cells, but their expansion has been a challenge until Pluri announced its proprietary MAIT immunotherapy platform in Global cancer immunotherap...
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy P...
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates PluriCDMO™, the Company’s contract development and manufacturing organization, recognized as a leading manufacturing partner offering scalability and mass scale production to a growing number of innovative life science companies HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today announced it has signed a tech transfe...
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Globa...
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply Collaboration aims to develop innovative production methods to increase global availability of vegetables, shorten supply chains and promote sustainable agriculture HAIFA, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), which transforms cells into solutions that promote global wellbeing and sustainability, has announced a strategic proof of concept (“POC”) agreement with a leading international agric...
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Invest...
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges $10 million funding round from U.S. and EU strategic investors, will accelerate growth and empower efficient cultivated meat, fish and seafood production at global scale, potentially tackling significant scalability challenges faced by the cultivated food industry Round led by global corporates with significant equipment, manufacturing, supply chain, and product development experience, alongside a second investment from Tnuva Group, Pluri and additional investors"Eve...
U.S. National Institutes of Health Exercises Option to Fund $1.4 Milli...
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract As part of Pluri’s previously announced $4.2 million 3-year with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), the option for the second year of the contract has been exercised to fund manufacturing, in-vitro, and in-vivo studies of Pluri’s cell therapyPLX-R18 is designed to be a first in class, effective treatment for ionizing radiation injuries that could be anticipated in the wake of a large-scale nuclear incidentWork dur...
Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate ...
Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale New production process will be developed based on Pluri’s proprietary 3D cell expansion technologyHuman breast milk oligosaccharides are known to shape the gut microbiota and thus provide to adultsGlobal elderly nutrition market is $39.7 billion in less than 10 years HAIFA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), which transforms cells into soluti...
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy...
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment Placental Mucosal Associated Invariant T (MAIT) cells are unique unconventional immune T cells which are particularly suitable for the treatment of solid tumors, a significant unmet medical needMAIT cells offer unique advantages compared to conventional T cellsMAIT cells hold immense potential for immunotherapy, but their expansion has been a challenge thus far. Pluri, leveraging two decades of cell expertise, has overcome this challenge with its proprietary technology, unlocking...
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for Ne...
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method Pluri’s patent enables mass-scale production of immune cell therapiesNew patented technology is applicable for the expansion of a variety of immune cellsTechnology sets stage for potential immune cell therapy advancements and targets an estimated total addressable market of HAIFA, Israel, April 08, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) (“Pluri” or the “Company”), which transforms cells into solutions that promote global wellbeing and sustainability, today...
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership...
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences Pluri’s business verticals leverage Company’s world-leading 3D cell expansion know-how, IP, and manufacturing facility to drive revenue and bring innovative cell-based solutions to numerous industries HAIFA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced leadership from its business ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.